Tag: MindMed - Psilocybin Alpha

Mind Medicine MindMed : MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

Mind Medicine MindMed : MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

Post published:October 16, 2020
Post category:Press Release

MindMed Announces $25 Million Bought Deal Public Offering

MindMed Announces $25 Million Bought Deal Public Offering

Post published:October 9, 2020
Post category:Press Release

MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines

MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines

Post published:October 5, 2020
Post category:Press Release

MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin

MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin

Post published:September 24, 2020
Post category:Press Release

MindMed Confirms No Material Change

MindMed Confirms No Material Change

Post published:September 23, 2020
Post category:Press Release

BREAKING: MindMed Applies to List on Nasdaq

BREAKING: MindMed Applies to List on Nasdaq

Post published:September 21, 2020
Post category:News

MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

Post published:August 25, 2020
Post category:Press Release

Can Taking MDMA with LSD Help Prevent a ‘Bad Trip’? New Clinical Trial Investigates

Can Taking MDMA with LSD Help Prevent a ‘Bad Trip’? New Clinical Trial Investigates

Post published:August 19, 2020
Post category:Clinical Trials / News

Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results

Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results

Post published:August 14, 2020
Post category:Press Release

MindMed Expanding R&D in Europe, Appoints Dr. Miri Halperin Wernli As President

MindMed Expanding R&D in Europe, Appoints Dr. Miri Halperin Wernli As President

Post published:August 13, 2020
Post category:Press Release

End of content

No more pages to load

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Shroom Stocks and Companies

News & Interviews

Data Bank

Get in Touch

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.

Contact Disclaimer Terms of Service Privacy Policy Twitter

© Psilocybin Alpha 2020